There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allogene Therapeutics (ALLO – Research Report) and Dynavax (DVAX – Research Report) with bullish sentiments.
Allogene Therapeutics (ALLO)
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Allogene Therapeutics, with a price target of $23.00. The company’s shares closed last Monday at $10.88.
According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Allogene Therapeutics is a Moderate Buy with an average price target of $26.75, representing a 153.6% upside. In a report issued on September 22, B.Riley Financial also maintained a Buy rating on the stock with a $18.00 price target.
Dynavax received a Buy rating and a $22.00 price target from JMP Securities analyst Roy Buchanan today. The company’s shares closed last Monday at $9.93.
According to TipRanks.com, Buchanan is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $24.67, representing a 140.9% upside. In a report issued on September 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALLO:
- 2 Utilities Stocks to Buy to Bank on Millennial Migration
- Mader Group (ASX:MAD) shares soar on dividend payments date
- Australian Stock Market Today – Tuesday September 27: What You Need to Know
- Demographic Trends Show That Netflix (NASDAQ: NFLX) Isn’t Dead; Here’s How
- Rosenblatt Securities Reaffirms Their Buy Rating on Splunk (SPLK)